Sort   by:  
 Page size 
UnknownConcordance Between Tissue <i>ALK</i> Detection by Immunohistochemistry and Plasma <i>ALK</i> Detection by Next-Generation Sequencing in the Randomized Phase 3 ALEX Study in Patients With Treatment-Naive Advanced <i>ALK</i>-Positive NSCLC.
Not available
S-EPMC9218556 | biostudies-literature
UnknownReal-World Comparative Effectiveness of First-Line Alectinib Versus Crizotinib in Patients With Advanced ALK-Positive NSCLC With or Without Baseline Central Nervous System Metastases.
Not available
S-EPMC10070922 | biostudies-literature
UnknownClinical experience and management of adverse events in patients with advanced ALK-positive non-small-cell lung cancer receiving alectinib.
Not available
S-EPMC9663323 | biostudies-literature
UnknownCirculating Cell-free DNA as a Prognostic Biomarker in Patients with Advanced ALK+ Non-small Cell Lung Cancer in the Global Phase III ALEX Trial.
Not available
S-EPMC9365376 | biostudies-literature
UnknownFinal efficacy and safety data, and exploratory molecular profiling from the phase III ALUR study of alectinib versus chemotherapy in crizotinib-pretreated ALK-positive non-small-cell lung cancer.
Not available
S-EPMC8777286 | biostudies-literature
UnknownSafety and Efficacy of Bevacizumab Plus Standard-of-Care Treatment Beyond Disease Progression in Patients With Advanced Non-Small Cell Lung Cancer: The AvaALL Randomized Clinical Trial.
Not available
S-EPMC6440713 | biostudies-literature
Sort   by:  
 Page size